Genelux GmbH


    • Company type:
      • Research & Development
    • Year founded:
    • 2004
    • Employees (at the site):
    • 5
    • Turnover range:
    • not available
    • Products/services:
    • Drug Development, Clinical Diagnostics, Drug Delivery, Immune Therapy, Oncology

    • Core competencies:
    • Competences for molecular design, preparation, processing ansd application of genetically modified vaccinia viruses and mammalian Genelux's vaccinia viruses, when injected into tumor bearing mice, colonize tumors, metastases, cancer cells. They grow and replicate within the tumors expressing inserted genes. Tumors are remitted. These scientific results will enable diagnosis and treatment of cancer, combining in vivo imaging (diagnostics) with bacteria/virus induced tumor regression (therapy), and should add a potent theragnostic alternative to existing therapies and diagnostics. Genelux GmbH, Bernried, Germany aims to translate the scientific results into commercial services and products.
      Its first candidate is in clincal trials

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Drug delivery
      • Biotechnology: Molecular diagnostics for humans
      • Biotechnology: Therapeutic drug development
    • Certification:
    • not available

    • Sales markets - target industries:
    • Global USA, EU, ROW
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Albert Röder (Mr.)
      - Management